Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Placing

14 Sep 2012 07:00

RNS Number : 2542M
Futura Medical PLC
14 September 2012
 



For immediate release

14 September 2012

 

Futura Medical plc

("Futura" or "the Company")

Placing to raise £2.08 million

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £2.08 million are being raised through the issue of 3,654,969 new ordinary shares of 0.2 pence each in Futura ("New Ordinary Shares") to existing institutional investors at a price of 57 pence per share. The Placing represents approximately 5% of the Company's issued share capital.

The £2.0 million net proceeds of the Placing, which is underwritten by Nomura Code Securities Limited, will be used to provide additional working capital. The Placing strengthens the balance sheet and will assist the Company in its out-licensing negotiations as well as the ongoing development of its product pipeline.

The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the New Ordinary Shares will commence on AIM at 8:00am on 19 September 2012.

Futura's total issued share capital following the admission of the New Ordinary Shares will be 77,369,081. The total number of voting rights in the Company will be 77,369,081.

James Barder, Futura's Chief Executive, said: "We're delighted to have completed this oversubscribed fundraising and by the support that we have received from our existing institutional shareholders."

For any further information please contact:

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive Officer

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

 

Nomura Code Securities Limited

+ 44 (0) 20 7776 1200

Phil Walker / Giles Balleny

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFXLLFLKFBBBV
Date   Source Headline
24th Apr 20257:00 amRNSChange of Broker
15th Apr 20257:00 amRNSResults for the Year ended 31 December 2024
10th Apr 20251:30 pmRNSNotice of Results and Investor Presentation
31st Mar 20257:00 amRNSBoard Appointment
30th Jan 20257:00 amRNSFY24 Trading Update and FY25 Outlook
15th Jan 20257:00 amRNSPositive results from WSD4000 Home User study
13th Jan 20257:00 amRNSRemuneration of Non-Executive Directors and TVR's
20th Dec 20247:58 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSBlock Listing Six Monthly Return
15th Nov 20247:00 amRNSTR-1: Notification of major holdings
4th Nov 20247:00 amRNSEncouraging New Product Development Pipeline
31st Oct 20247:00 amRNSTotal Voting Rights
7th Oct 20247:00 amRNSFurther milestone payment triggered post US launch
1st Oct 20247:00 amRNSTotal Voting Rights
13th Sep 20247:00 amRNSDirectors’ / PDMR Dealing
11th Sep 20245:43 pmRNSTrinity Delta research note & consensus forecasts
10th Sep 20247:00 amRNSFutura Medical - Interim Results 2024
2nd Sep 202410:47 amRNSUpdate on US Launch
2nd Sep 20247:00 amRNSUpdate on US launch
19th Aug 20247:00 amRNSNotice of Results
1st Aug 20247:05 amRNSUpdate on US launch
1st Jul 20242:13 pmRNSTotal Voting Rights
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
20th Jun 20244:12 pmRNSResult of AGM
20th Jun 20247:00 amRNSAGM Statement
31st May 20247:00 amRNSBlock Listing Six Monthly Review
24th May 20247:00 amRNSNotice of AGM and availability of Annual Report
29th Apr 20247:00 amRNSDirectors’ / PDMR Dealing and Grant of Options
10th Apr 20247:00 amRNSResults for the Year ended 31 December 2023
25th Mar 20247:00 amRNSNotice of Results and Investor Presentation
14th Feb 20247:00 amRNSEroxon to be available on prescription
6th Feb 20247:01 amRNSTrading Update
6th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
17th Jan 20247:00 amRNSDirector/PDMR Dealing
17th Jan 20247:00 amRNSRemuneration of Non-Exec Directors & Voting Rights
15th Jan 20247:00 amRNSFutura Medical extends collaboration with Cooper
9th Jan 20247:00 amRNSAppointment of Roy Davis as Non-Executive Director
30th Nov 20233:10 pmRNSTotal Voting Rights
30th Nov 20233:10 pmRNSBlock Listing Six Monthly Return
7th Nov 20237:00 amRNSFutura expands partnership with M8 Pharmaceuticals
2nd Nov 20233:34 pmRNSEroxon Awarded “New Product of the Year” by Boots
31st Oct 20237:00 amRNSBlock Listing Application and Total Voting Rights
25th Oct 20237:00 amRNSEroxon® Granted Marketing Authorisation in Mexico
19th Oct 20237:00 amRNSEroxon Launches in the United Arab Emirates
10th Oct 20237:00 amRNSDirectors’/PDMR Dealing and Grant of Options
2nd Oct 20237:00 amRNSEuropean Patent Granted for MED3000 until 2040
18th Sep 20237:00 amRNSFutura Medical - Interim Results 2023
18th Aug 20237:00 amRNSFutura Medical - Notice of Interim Results
31st Jul 20237:00 amRNSFutura Medical - Total Voting Rights
18th Jul 202311:04 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.